Multigene analysis of Rb pathway and apoptosis control in esophageal squamous cell carcinoma identifies patients with good prognosis
Open Access
- 26 November 2002
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 103 (4) , 445-454
- https://doi.org/10.1002/ijc.10850
Abstract
Deregulation of cell‐cycle G1‐restriction point control by disruption of Rb‐pathway components is a frequent event in cancer. In concert with the inactivation of cell death pathways, such events not only contribute to tumor development but also determine the intrinsic and acquired resistance to cancer therapy and, ultimately, disease prognosis. We previously observed that the cyclin‐dependent kinase inhibitor p16INK4a and the proapoptotic Bcl‐2 homolog Bax are positive prognostic factors and identify patients with good prognosis in esophageal squamous cell carcinoma (SCC). In the present study, we therefore extend our analysis to additional genes controlling the G1 restriction point and apoptosis, respectively. This retrospective analysis was performed in a cohort of 53 patients undergoing surgery for esophageal SCC with curative intent, i.e., R0 resection. Protein expression profiles of cyclin D1, p16INK4a, Rb, p21CIP/WAF‐1, p53, Bax and Bcl‐2 were analyzed by immunohistochemistry and compared to p53 mutational status, as determined by SSCP‐PCR of exons 5–8. Loss of p16INK4a, Rb, p21CIP/WAF‐1 or Bax and overexpression of cyclin D1 were associated individually with shorter overall survival, while Bcl‐2 expression and p53 mutation were not of prognostic relevance. The longest survival was observed in a subgroup of patients whose tumors bore a combination of favorite genotypes, i.e., low cyclin D1 and high Rb, p21CIP/WAF‐1, p16INK4a and Bax protein expression. These results show that multigene analyses based on limited sets of functionally linked genes reliably identify patients with good vs. poor prognosis.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft
This publication has 40 references indexed in Scilit:
- Ceramide induces mitochondrial activation and apoptosis via a Bax-dependent pathway in human carcinoma cellsOncogene, 2002
- Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemiaLeukemia, 2002
- Analysis of p53/BAX in primary colorectal carcinoma: Low BAX protein expression is a negative prognostic factor in UICC stage III tumorsInternational Journal of Cancer, 2002
- The apoptosis promoting Bcl-2 homologues Bak and Nbk/Bik overcome drug resistance in Mdr-1-negative and Mdr-1-overexpressing breast cancer cell linesOncogene, 2002
- DNA microarrays identification of primary and secondary target genes regulated by p53Oncogene, 2001
- Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosisEuropean Journal of Surgical Oncology, 1997
- Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice.Journal of Clinical Investigation, 1996
- Expression of the bcl‐2 gene family in normal and malignant breast tissue: Low bax‐α expression in tumor cells correlates with resistance towards apoptosisInternational Journal of Cancer, 1995
- Tumor suppressor p53 is a direct transcriptional activator of the human bax geneCell, 1995
- P53 protein expression and prognosis in squamous cell carcinoma of the esophagusCancer, 1994